March 2018

The GLP-1 receptor agonist is a similar, longer-acting formula to that of liraglutide, another successful therapy from Novo Nordisk that was recently approved for its second indication of lowering cardiovascular risk.

With the ongoing rollout of Mayo Clinic’s new EHR system, Epic, the hospital continues to build on its commitment to integrated care that patients have come to expect.

Kevin Maki discussed the constant need for more options, the importance of balancing the cost and benefits of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and the impact of the new hypertension guidelines.

In recent years, cholesteryl ester transfer protein (CETP) inhibition has become contentious in lipidology and cardiology circles. Many believe that we have reached the end of the CETP inhibition class, and not without good reason—many drug makers have failed to bring the class to market.

Although the factor Xa (FXa) inhibitor oral anticoagulants have fewer drug interactions and are without burdens associated with warfarin, such as blood test monitoring, dosage adjustment, and diet restriction, they also lack an approved antidote to their anticoagulant effect.

Although about 9.4% of the US population has been diagnosed with diabetes, almost one-quarter of that group—23.8%—are as yet undiagnosed.